Controlled Release of Immunosuppressants from Synthetic Nanocarriers

The European Patent Office published European Patent Application EP3682878A1 for Cartesian Therapeutics, Inc., covering synthetic nanocarriers engineered for controlled release of immunosuppressant drugs. The invention relates to polymer-based nanocarriers designed to provide sustained delivery of immunosuppressant compounds, potentially useful in treating autoimmune conditions. The patent is classified under A61K 31/445, A61K 9/16, and B82Y 5/00, among other IPC codes.

Competitors developing nanocarrier-based immunosuppressant delivery systems should review this patent portfolio when designing products to avoid potential infringement. The patent provides territorial protection across designated European states including Germany, France, the United Kingdom, Italy, Spain, and 26 other European countries.